Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: An analysis with considerations for future studies.
J Eur Acad Dermatol Venereol
; 38(4): e302-e303, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-37907280
Assuntos
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Anticorpos Monoclonais Humanizados
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article